Senores Pharmaceuticals Limited has successfully completed the first phase of its strategic acquisition of Apnar Pharma Private Limited. The company announced on January 16, 2026, that it has acquired 75% equity stake in the target company, marking a significant milestone in the ₹91.00 crore acquisition deal initially announced in December 2025.

Acquisition Completion Details

The pharmaceutical company has completed the acquisition of 56,63,804 equity shares from existing shareholders of Apnar Pharma Private Limited. This transaction represents the first tranche of the two-phase acquisition structure outlined in the original Share Purchase Agreement.

Original Acquisition Framework

The acquisition was initially approved by the Management Committee of the Board of Directors on December 15, 2025, with a total enterprise value of ₹91.00 crores. The deal structure combines strategic value creation with phased implementation to ensure smooth integration.

Manufacturing Facility Assets

The acquired facility in Jambusar, Gujarat represents a state-of-the-art pharmaceutical manufacturing operation that commenced in 2021. The facility received USFDA approval in September 2022 and maintains multiple international regulatory certifications including UK-MHRA and Health Canada approvals.

Production Capabilities

The facility demonstrates significant production capabilities across multiple dosage forms with substantial expansion potential. Current operations serve regulated markets including the US, UK, and Canada.

Strategic Value and Market Access

The acquisition provides immediate access to regulated markets beyond Senores Pharmaceuticals' current US presence. According to Swapnil Shah, Promoter Managing Director, the facility will enable manufacturing of select US products from India, improving operational leverage and supporting margin expansion.

Key strategic benefits include enhanced market access across regulated territories, revenue and cost synergies through cross-selling, backward integration via in-house manufacturing, and expansion of product portfolio. The deal includes 5 approved ANDAs representing a total addressable market exceeding $700 million.

Regulatory Compliance

The transaction has been disclosed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed both BSE Limited and National Stock Exchange of India Limited about the completion of the first tranche, ensuring full compliance with regulatory requirements.

Senores Pharmaceuticals has announced a comprehensive warrant issuance program following board approval at its meeting held on January 07, 2026. The pharmaceutical company has received authorization for issuing convertible equity warrants worth ₹950.04 crores, representing a significant capital mobilization initiative targeting promoter and promoter group entities.

Warrant Issuance Specifications

The board has structured a detailed warrant offering with specific parameters for potential investors. The preferential issue involves fully convertible equity warrants that provide holders the right to subscribe to equity shares within a defined timeframe.

Investor Details and Shareholding Impact

The warrant issuance targets five specific investors from the promoter and promoter group category. The allocation demonstrates strategic capital infusion from existing stakeholders, with varying investment commitments across different entities.

Payment Structure and Conversion Terms

The warrant structure follows regulatory guidelines with a phased payment mechanism. Warrant holders must pay 25% of the exercise price at allotment, with the remaining 75% payable upon conversion to equity shares. Each warrant carries the right to subscribe to one equity share of ₹10.00 face value.

The conversion window extends for 18 months from the allotment date, providing flexibility for warrant holders to exercise their rights based on market conditions. Unconverted warrants will automatically lapse after the exercise period, with amounts paid being forfeited.

Corporate Governance and Regulatory Compliance

The board has established January 01, 2026, as the relevant date for determining the floor price under SEBI ICDR Regulations. An Extraordinary General Meeting has been scheduled for January 31, 2026, at 12:30 PM through video conferencing to obtain shareholder approval for the preferential issue.

The company has appointed M/s. Mukesh H. Shah & Co., Practicing Company Secretaries, as scrutinizer for the e-voting process. The cut-off date for EGM notice dispatch has been fixed as January 02, 2026, ensuring compliance with regulatory timelines and transparency requirements.